author-photo

Tony Navas

Astellas Pharma

15

Papers

54

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (33)
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells

2018 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (5)
Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Effective implementation of novel MET pharmacodynamic assays in translational studies

2017 Annals of Translational Medicine
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Anticorps monoclonaux anti-cd133 et compositions et méthodes associées

2016
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 5279: Establishing robust pharmacodynamic (PD) immunofluorescence assays of clinical biopsies at the National Cancer Institute: Optimized quality control procedures for the evaluation of DNA damage response and epithelial-mesenchymal transition (EMT) biomarkers

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)